Effect of probiotic and metformin combination therapy on insulin resistance in polycystic ovary syndrome compared with metformin alone
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252716Keywords:
Insulin resistance, Metformin, PCOS, ProbioticAbstract
Background: Insulin resistance in PCOS can be aggravated by gut microbiota dysbiosis. Probiotics may improve microbial balance and insulin sensitivity and, in combination with metformin, improve glycemic control while reducing side effects. This study aimed to compare the effects of probiotic–metformin combination therapy versus metformin alone on insulin resistance in PCOS patients.
Methods: This randomized controlled trial at BSMMU included 60 infertile women with PCOS and insulin resistance. Participants were randomized into two groups: one received probiotics (Lactobacillus and Bifidobacterium, 4 billion CFU twice daily for 12 weeks) plus metformin and the control group received metformin alone. Fasting blood sugar and insulin were measured pre- and post-treatment to assess insulin resistance.
Results: In the experimental group (probiotics+metformin), FBS, fasting insulin and HOMA-IR decreased significantly after 12 weeks (5.1±0.6 vs 5.5±0.9 mmol/l; 10.2±3.8 vs 17.5±5.5 µIU/ml; 2.3±0.9 vs 4.3±1.5). Similar significant reductions were observed in the control group (metformin alone) for FBS (5.3±0.6 vs 5.4±0.5 mmol/l), fasting insulin (10.8±4.3 vs 17.6±7.4 µIU/ml) and HOMA-IR (2.6±1.4 vs 4.2±1.6). However, the mean changes between groups were not statistically significant.
Conclusions: Probiotic–metformin therapy improved insulin resistance, but not significantly more than metformin alone and had fewer, non-significant side effects.
Metrics
References
Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–97. DOI: https://doi.org/10.1016/S0140-6736(07)61345-2
The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7. DOI: https://doi.org/10.1093/humrep/deh098
Tan S, Scherag A, Janssen OE, Hahn S, Lahner H, Dietz T, et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet. 2010;11:1–9. DOI: https://doi.org/10.1186/1471-2350-11-12
Speroff L, Taylor HS, Pal L, Seli E. Clinical Gynecologic Endocrinology and Infertility. 9th ed. Wolters Kluwer; 2020. p. 405.
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–31. DOI: https://doi.org/10.1038/nrendo.2010.217
Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y, Tang L. Association between polycystic ovary syndrome and gut microbiota. PLoS One. 2016;11(4):153196. DOI: https://doi.org/10.1371/journal.pone.0153196
Lloyd-Price J, Mahurkar A, Rahnavard G, Crabtree J, Orvis J, Hall AB, et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature. 2017;550(7674):61–6. DOI: https://doi.org/10.1038/nature23889
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. DOI: https://doi.org/10.1038/nature11450
Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64. DOI: https://doi.org/10.1038/nature13568
Zhang J, Sun Z, Jiang S, Bai X, Ma C, Peng Q, et al. Probiotic Bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis. mSystems. 2019;4(2):128–19. DOI: https://doi.org/10.1128/mSystems.00017-19
Liu R, Zhang C, Shi Y, Shen J, Zhao L, Ding X. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol. 2017;8:2345. DOI: https://doi.org/10.3389/fmicb.2017.00324
Ma J, Lin TC, Liu W. Gastrointestinal hormones and polycystic ovary syndrome. Endocrine. 2014;47:668–78. DOI: https://doi.org/10.1007/s12020-014-0275-1
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14. DOI: https://doi.org/10.1038/nrgastro.2014.66
Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007;23(1):62–8. DOI: https://doi.org/10.1016/j.nut.2006.09.002
Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19(40):6911–8. DOI: https://doi.org/10.3748/wjg.v19.i40.6911
Heshmati J, Farsi F, Yosaee S, Razavi M, Rezaeinejad M, Karimie E, Sepidarkish M. The effects of probiotics or synbiotics supplementation in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized clinical trials. Probiotics Antimicrob Proteins. 2019;11:1236–47. DOI: https://doi.org/10.1007/s12602-018-9493-9
Hadi A, Moradi S, Ghavami A, Khalesi S, Kafeshani M. Effect of probiotics and synbiotics on selected anthropometric and biochemical measures in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Clin Nutr. 2020;74(4):543–7. DOI: https://doi.org/10.1038/s41430-019-0434-9
Lye HS, Rusul G, Liong MT. Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol. J Dairy Sci. 2010;93(4):1383–92. DOI: https://doi.org/10.3168/jds.2009-2574
Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361(9372):1894–901. DOI: https://doi.org/10.1016/S0140-6736(03)13493-9
Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–56. DOI: https://doi.org/10.1038/nrendo.2013.256
Chen Z, Wei H, Zhao X, Xin X, Peng L, Ning Y, et al. Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP‐2 and MMP‐9 via H19/miR‐29b‐3p and AKT/mTOR/autophagy signaling pathways. J Cell Physiol. 2019;234(11):19964–76. DOI: https://doi.org/10.1002/jcp.28594
Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci. 2010;1205:192–8. DOI: https://doi.org/10.1111/j.1749-6632.2010.05679.x
Cheang KI, Huszar JM, Best AM, Sharma S, Essah PA, Nestler JE. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diabetes Vasc Dis Res. 2009;6(2):110–9. DOI: https://doi.org/10.1177/1479164109336050
Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473–81. DOI: https://doi.org/10.1111/dom.12854
Şahin K, Şahintürk Y, Köker G, Köker GÖ, Bostan F, Kök M, et al. Metformin with versus without concomitant probiotic therapy in newly diagnosed patients with type 2 diabetes or prediabetes: a comparative analysis in relation to glycemic control, gastrointestinal side effects and treatment compliance. Turk J Gastroenterol. 2022;33(11):925. DOI: https://doi.org/10.5152/tjg.2022.211063
Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation and treatment. J Ovarian Res. 2023;16(1):9. DOI: https://doi.org/10.1186/s13048-022-01091-0
Traub ML. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World J Diabetes. 2011;2(3):33–9. DOI: https://doi.org/10.4239/wjd.v2.i3.33
Angoorani P, Ejtahed HS, Ettehad Marvasti F, Taghavi M, Mohammadpour Ahranjani B, Hasani-Ranjbar S, Larijani B. The effects of probiotics, prebiotics and synbiotics on polycystic ovarian syndrome: an overview of systematic reviews. Front Med. 2023;10:1141355. DOI: https://doi.org/10.3389/fmed.2023.1141355
Shoaei T, Heidari-Beni M, Tehrani HG, Esmaillzadeh A, Askari G. Effects of probiotic supplementation on pancreatic β-cell function and C-reactive protein in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Int J Prev Med. 2015;6:27. DOI: https://doi.org/10.4103/2008-7802.153866
Zafar U, Iqbal N, Mughal F, Quraishi F, Bijarani AN, Muneer M. Effect of metformin and its combination with probiotic on menstrual irregularity and TSH levels in patients with polycystic ovarian syndrome: a randomized controlled trial. J Pharm Res Int. 2021;33(33A):29–38. DOI: https://doi.org/10.9734/jpri/2021/v33i33A31768
Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M, Memarzadeh MR, Asemi Z. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017;20(4):254–61. DOI: https://doi.org/10.1080/14647273.2017.1283446
Masaeli A, Nayeri H, Mirzaee M. Effect of metformin treatment on insulin resistance markers and circulating irisin in women with polycystic ovarian syndrome (PCOS). Horm Metab Res. 2019;51(9):575–9. DOI: https://doi.org/10.1055/a-0896-1130
Kamrul-Hasan ABM, Aalpona FTZ, Mustari M, Selim S. Prevalence and characteristics of women with polycystic ovary syndrome in Bangladesh–A narrative review. Bangladesh J Endocrinol Metab. 2023;2(1):20–8. DOI: https://doi.org/10.4103/bjem.bjem_14_22
Huang LH, Liao YL, Hsu CH. Waist circumference is a better predictor than body mass index of insulin resistance in type 2 diabetes. Obes Res Clin Pract. 2012;6(4):314–20. DOI: https://doi.org/10.1016/j.orcp.2011.11.003
Zamila BM, Banu H, Morshed MS, Shah S, Begum A, Sultana T, et al. Manifestations of polycystic ovary syndrome are similar regardless of the degree of menstrual cycle variation. Int J Hum Health Sci. 2022;6:96–103. DOI: https://doi.org/10.31344/ijhhs.v6i1.383
Samimi M, Dadkhah A, Haddad Kashani H, Tajabadi-Ebrahimi M, Seyed Hosseini E, Asemi Z. The effects of synbiotic supplementation on metabolic status in women with polycystic ovary syndrome: a randomized double-blind clinical trial. Probiotics Antimicrob Proteins. 2019;11:1355–61. DOI: https://doi.org/10.1007/s12602-018-9405-z
Nawrocka J, Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecol Endocrinol. 2007;23(4):231–7. DOI: https://doi.org/10.1080/09513590701260193
Attia GM, Almouteri MM, Alnakhli FT, Almouteri M, Alnakhli F. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility. Cureus. 2023;15(8):87532. DOI: https://doi.org/10.7759/cureus.44493
Gu R, Syed N. The efficacy of metformin treatment on insulin resistance and hyperandrogenism in lean women with polycystic ovary syndrome: a literature review. Undergrad Res Nat Clin Sci Technol J. 2023;1–15. DOI: https://doi.org/10.26685/urncst.417
Memon H, Abdulla F, Reljic T, Alnuaimi S, Serdarevic F, Asimi ZV, et al. Effects of combined treatment of probiotics and metformin in management of type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2023;202:110806. DOI: https://doi.org/10.1016/j.diabres.2023.110806
Kumar VM, Ahmed Z, Rahman SAU. Probiotics efficacy and safety as add-on therapy to metformin in type 2 diabetes mellitus. Indian J Public Health Res Dev. 2022;13(4):317–21. DOI: https://doi.org/10.37506/ijphrd.v14i4.18637
Soccol CR, Vandenberghe LDS, Spier MR, Medeiros ABP, Yamaguishi CT, Lindner JDD, et al. The potential of probiotics: a review. Food Technol Biotechnol. 2010;48(4):48–63.
Olgun A. “Metformin-resistant” folic acid producing probiotics or folic acid against metformin’s adverse effects like diarrhea. Med Hypotheses. 2017;106:33–4. DOI: https://doi.org/10.1016/j.mehy.2017.07.009
Downloads
Published
How to Cite
Issue
Section
